Trust Co. of Vermont Sells 131 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Trust Co. of Vermont decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 36.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 231 shares of the pharmaceutical company’s stock after selling 131 shares during the period. Trust Co. of Vermont’s holdings in Vertex Pharmaceuticals were worth $103,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. PFG Investments LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.3% in the 2nd quarter. PFG Investments LLC now owns 1,872 shares of the pharmaceutical company’s stock worth $833,000 after buying an additional 60 shares during the period. Columbia Asset Management bought a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $222,000. Chicago Capital LLC raised its holdings in shares of Vertex Pharmaceuticals by 3.8% in the second quarter. Chicago Capital LLC now owns 12,875 shares of the pharmaceutical company’s stock valued at $5,732,000 after acquiring an additional 469 shares in the last quarter. Lee Johnson Capital Management LLC purchased a new stake in Vertex Pharmaceuticals in the second quarter worth about $721,000. Finally, Janney Montgomery Scott LLC grew its holdings in Vertex Pharmaceuticals by 4.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 71,890 shares of the pharmaceutical company’s stock worth $32,005,000 after acquiring an additional 3,271 shares in the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on VRTX shares. BMO Capital Markets set a $530.00 price target on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a report on Tuesday, August 5th. Leerink Partners raised shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and reduced their price objective for the stock from $458.00 to $456.00 in a research note on Thursday, September 25th. Stifel Nicolaus lowered their target price on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a report on Tuesday, August 5th. Wall Street Zen downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Finally, Scotiabank decreased their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $493.81.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $408.85 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.88. The company has a market cap of $104.83 billion, a PE ratio of 29.22 and a beta of 0.43. The business has a 50-day simple moving average of $400.44 and a two-hundred day simple moving average of $443.73.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bruce I. Sachs purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.